当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.

Randomized comparison of early and late vaccination with inactivated poliovirus vaccine after allogeneic BMT.

Abstract：

:Forty-five adult HLA-matched sibling BMT recipients were randomized to receive inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months (early group, n = 23) or at 18, 20 and 26 months after BMT (late group, n = 22). Ninety-five percent of the early group patients had protective antibody titres of > or = 4 to poliovirus type 1 (PV1), poliovirus type 2 (PV2) and poliovirus type 3 (PV3) by a microneutralization assay prior to the first vaccination, at 6 months after BMT. The corresponding proportion for the late group patients was only 67% at 18 months. The antibody responses 1 month after each of the three IPV doses were similar in the two vaccination groups, except that four-fold responses occurred more frequently after the first dose to PV2 and PV3 in the late group. All patients had a protective antibody titre to all poliovirus serotypes 1 and 22 months after the third vaccine dose, except one patient in the early group who lacked antibodies to PV3 at 22 months. Acute GVHD accelerated the decrease of poliovirus antibody titres prior to vaccination but had no influence on vaccination response. Chronic GVHD neither influenced the patient's ability to retain poliovirus antibodies prior to vaccination nor impaired responses to vaccinations. A vaccination schedule consisting of three IPV doses was equally immunogenic when started at 6 or 18 months after allogeneic BMT.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Parkkali T,Stenvik M,Ruutu T,Hovi T,Volin L,Ruutu P

doi

10.1038/sj.bmt.1700959

subject

Has Abstract

pub_date

1997-10-01 00:00:00

pages

663-8

issue

8

eissn

0268-3369

issn

1476-5365

journal_volume

20

pub_type

临床试验,杂志文章,随机对照试验

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • Successful allogeneic bone marrow transplant for chronic myeloid leukaemia despite previous interferon-induced cardiomyopathy.

    abstract：:We report a patient with CML who developed a reversible dilated cardiomyopathy with cardiac failure following 10 months of IFN therapy. Despite the previous cardiomyopathy, he tolerated subsequent allogeneic BMT without any adverse cardiac events. Reversible IFN-induced cardiomyopathy should not be considered a contra...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701188

    authors： Broady R,Hawkins T,Browett P,Palmer S

    更新日期：1998-04-01 00:00:00

  • Hematopoietic SCT modulates gut inflammation in experimental inflammatory bowel disease.

    abstract：:Hematopoietic SCT (HSCT) and high-dose chemotherapy are being explored as therapy for various human refractory immune-mediated conditions, including inflammatory bowel diseases (IBD). Nevertheless, the exact immunological mechanisms by which the BM cells (BMCs) or immunosuppression provide remission from these disease...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.6

    authors： Godoi DF,Cardoso CR,Ferraz DB,Provinciatto PR,Cunha FQ,Silva JS,Voltarelli JC

    更新日期：2010-10-01 00:00:00

  • A randomized controlled trial of plasma real-time PCR and antigenemia assay for monitoring CMV infection after unrelated BMT.

    abstract：:Preemptive therapy is the standard strategy for preventing CMV disease after allogeneic hematopoietic SCT. In this study, unrelated BMT recipients were randomly assigned to a plasma real-time PCR group or an antigenemia group to compare the value of these monitoring tools for CMV reactivation. Ganciclovir (GCV) was st...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/bmt.2009.337

    authors： Kanda Y,Yamashita T,Mori T,Ito T,Tajika K,Mori S,Sakura T,Hara M,Mitani K,Kurokawa M,Akashi K,Harada M

    更新日期：2010-08-01 00:00:00

  • Campylobacter jejuni bacteremia and Guillain-Barré syndrome in a patient with GVHD after allogeneic BMT.

    abstract：:Guillain-Barré syndrome is a rare neurologic complication after allogeneic BMT. In the non-transplant setting, Guillain-Barré syndrome has typically been associated with antecedent acute infections and numerous reports have suggested an association between Campylobacter jejuni infection and the subsequent development ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Hagensee ME,Benyunes M,Miller JA,Spach DH

    更新日期：1994-03-01 00:00:00

  • Growth, growth hormone and final height after BMT. Possible recovery of irradiation-induced growth hormone insufficiency.

    abstract：:The aim of the present study was to assess growth, final height, growth hormone (GH) secretion and growth factors after BMT including TBI in childhood. The median age of the 25 participants was 11.3 years at BMT, and a median of 7.5 years had elapsed since BMT. The median height standard deviation score (SDS) declined...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Holm K,Nysom K,Rasmussen MH,Hertz H,Jacobsen N,Skakkebaek NE,Krabbe S,Müller J

    更新日期：1996-07-01 00:00:00

  • Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.

    abstract：:Pentaglobin is a commercial immunoglobulin preparation which is enriched specifically for IgM and also contains antibodies that are capable of neutralizing endotoxins. Its potential use in treating patients with acute graft-versus-host disease (GVHD) was studied in a phase I/II study. Pentaglobin was administered at a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Klingemann HG,Barnett MJ,Reece DE,Shepherd JD,Phillips GL

    更新日期：1990-09-01 00:00:00

  • Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease.

    abstract：:We investigated the use of 'prophylactic' donor lymphocyte infusions (DLI) containing 1 x 107 CD3+ cells, given at 30, 60 and 90 days post-allogeneic blood and marrow transplantation (BMT), following conditioning with fludarabine 30 mg/m(2)/4 days and melphalan 70 mg/m(2)/2 days. GVHD prophylaxis consisted of cyclospo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702726

    authors： de Lima M,Bonamino M,Vasconcelos Z,Colares M,Diamond H,Zalcberg I,Tavares R,Lerner D,Byington R,Bouzas L,da Matta J,Andrade C,Carvalho L,Pires V,Barone B,Maciel C,Tabak D

    更新日期：2001-01-01 00:00:00

  • Pulmonary toxicity associated with high dose chemotherapy in the treatment of solid tumors with autologous marrow transplant: an analysis of four chemotherapy regimens.

    abstract：:We retrospectively reviewed the pulmonary toxicity of six high dose chemotherapy protocols using four chemotherapy regimens in the treatment of solid tumors. All protocols used either high dose cyclophosphamide or ifosfamide in combination with one to three additional chemotherapeutic agents. In each protocol autologo...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Seiden MV,Elias A,Ayash L,Hunt M,Eder JP,Schnipper LE,Frei E 3rd,Antman KH

    更新日期：1992-07-01 00:00:00

  • Evaluation of chimerism after bone marrow transplantation with single locus minisatellite DNA probes.

    abstract：:The origin of cells in almost all allogeneic donor-recipient pairs can be determined through the use of highly polymorphic minisatellite DNA probes. Single-locus probes were cloned from hypervariable fragments in a human DNA fingerprint detected with a multi-locus probe. While each probe is highly polymorphic and locu...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Harano H,Maruta A,Matsuzaki M,Kanamori H,Fukawa H,Noguchi T,Miyashita H,Ogawa K,Motomura S,Kodama F

    更新日期：1993-09-01 00:00:00

  • ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

    abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704579

    authors： Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

    更新日期：2004-08-01 00:00:00

  • Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia.

    abstract：:To evaluate the efficacy and toxicity of two different etoposide (VP-16) dosages (30 or 45 mg/kg) in combination with busulfan/cyclophosphamide as conditioning therapy followed by stem cell transplantation in acute myeloid leukemia (AML), 90 patients with AML received either 30 mg/kg (n = 60) or 45 mg/kg (n = 30) etop...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702598

    authors： Kröger N,Zabelina T,Sonnenberg S,Krüger W,Renges H,Stute N,Finkenstein F,Mayer U,Holstein K,Fiedler W,Colberg H,Sonnen R,Kuse R,Braumann D,Metzner B,del Valle F,Erttmann R,Kabisch H,Zander AR

    更新日期：2000-10-01 00:00:00

  • Pneumoperitoneum without peritonitis after allogeneic peripheral blood stem cell transplantation.

    abstract：:Allogeneic blood stem cell transplantation is associated with multiple complications. We report a case of pneumoperitoneum without peritonitis associated with colonic pneumatosis in a patient who had undergone an allogeneic peripheral blood cell transplant ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701255

    authors： de Magalhaes-Silverman M,Simpson J,Ball E

    更新日期：1998-06-01 00:00:00

  • Peripheral blood stem cell support does not accelerate haemopoietic recovery from miniBEAM chemotherapy.

    abstract：:Intermediate-dose salvage therapy is frequently given for relapsed and resistant lymphomas and is usually intensely myelosuppressive. In an attempt to reduce the haematological toxicity of miniBEAM, one of the commonly used salvage regimens, peripheral blood stem cell (PBSC) support was given to 21 consecutive patient...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Fielding AK,Goldstone AH,Sullivan AM,Watts MJ,Jamieson E,Linch DC

    更新日期：1996-09-01 00:00:00

  • Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia.

    abstract：:For patients with ALL who relapse following allo-SCT, only a second SCT provides a realistic chance for long-term disease remission. We retrospectively analyzed the outcomes of 31 patients with relapsed ALL after a prior allo-SCT, who received a second SCT (SCT2) at our center. With a median follow-up of 3 years, 1- a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.195

    authors： Poon LM,Bassett R Jr,Rondon G,Hamdi A,Qazilbash M,Hosing C,Jones RB,Shpall EJ,Popat UR,Nieto Y,Worth LL,Cooper L,De Lima M,Champlin RE,Kebriaei P

    更新日期：2013-05-01 00:00:00

  • Allo-SCT conditioning for myelodysplastic syndrome and acute myeloid leukemia with clofarabine, cytarabine and ATG.

    abstract：:The application of myeloablative Allo-SCT is limited by its associated morbidity and mortality. Reduced-intensity conditioning regimens attempt to diminish these, but are associated with a higher risk of disease relapse. Given the evidence of activity of clofarabine and cytarabine in myelodysplastic syndrome/acute mye...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/bmt.2008.423

    authors： Martin MG,Uy GL,Procknow E,Stockerl-Goldstein K,Cashen A,Westervelt P,Abboud CN,Augustin K,Luo J,DiPersio JF,Vij R

    更新日期：2009-07-01 00:00:00

  • Risk factors and prognosis of hepatic acute GvHD after allogeneic hematopoietic cell transplantation.

    abstract：:Hepatic acute GvHD (aGvHD) is associated with high mortality owing to poor response to immunosuppressive therapy. The pathogenesis of hepatic aGvHD differs from that of other lesions, and specific risk factors related to pre-transplant liver conditions should be determined. We conducted a cohort study by using a Japan...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,多中心研究

    doi：10.1038/bmt.2015.205

    authors： Arai Y,Kanda J,Nakasone H,Kondo T,Uchida N,Fukuda T,Ohashi K,Kaida K,Iwato K,Eto T,Kanda Y,Nakamae H,Nagamura-Inoue T,Morishima Y,Hirokawa M,Atsuta Y,Murata M,GVHD working group of the Japan Society for Hematopoietic Ce

    更新日期：2016-01-01 00:00:00

  • The clinical diagnosis of acute graft-versus-host disease: a diversity of views amongst marrow transplant centers.

    abstract：:The diagnosis and grading of acute graft-versus-host disease (AGVHD) is based on a spectrum of clinical and laboratory features. To evaluate the reliability of current diagnostic and scoring criteria, six clinical vignettes were evaluated by 49 transplant physicians from 42 bone marrow transplant center worldwide. Res...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Atkinson K,Horowitz MM,Biggs JC,Gale RP,Rimm AA,Bortin MM

    更新日期：1988-01-01 00:00:00

  • Cost-effectiveness of CD34+ dose in peripheral blood progenitor cell transplantation for non-Hodgkin's lymphoma patients: a single centre study.

    abstract：:Intensive high-dose chemotherapy with peripheral blood progenitor cell (PBPC) transplantation is a common strategy for aggressive non-Hodgkin's lymphomas (NHL). A retrospective cost-effectiveness analysis of CD34+ cell dose was carried out. Between 1994 and 1998, 28 patients were included. Efficacy was measured by the...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702378

    authors： Limat S,Woronoff-Lemsi MC,Deconinck E,Racadot E,Jacquet M,Herve P,Cahn JY

    更新日期：2000-05-01 00:00:00

  • A scoping review of caregiver burden during allogeneic HSCT: lessons learned and future directions.

    abstract：:The extant literature documents burden among caregivers of patients undergoing a hematopoietic stem cell transplantation (HSCT), but little is known about the burden of caregivers of patients receiving outpatient and homebound HSCTs. This scoping study sought to evaluate what is known about the burden of the increasin...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2016.164

    authors： Applebaum AJ,Bevans M,Son T,Evans K,Hernandez M,Giralt S,DuHamel K

    更新日期：2016-11-01 00:00:00

  • Adhesion molecules on peripheral blood-derived CD34+ cells: effects of cryopreservation and short-term ex vivo incubation with serum and cytokines.

    abstract：:The homing of hematopoietic precursor cells (HPC) within the bone marrow is most likely to be mediated by specific adhesion via surface receptors to cellular and extracellular matrix (ECM) components and to be regulated by cytokines. We investigated the effects of serum and cytokines on the expression of adhesion mole...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1701484

    authors： Koenigsmann MP,Koenigsmann M,Notter M,Neuloh M,Mücke C,Thiel E,Berdel WE

    更新日期：1998-12-01 00:00:00

  • Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease.

    abstract：:When allogeneic BMT is used for the treatment of leukemia, depletion of T cells from the donor BM to avoid GVHD may be accompanied by persistence of host cells and post-transplant relapse. In this report, a murine model of MHC-compatible BMT was used to show that delayed infusion of immunocompetent donor cells early a...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Johnson BD,Drobyski WR,Truitt RL

    更新日期：1993-04-01 00:00:00

  • Blood and marrow transplantation during the emerging COVID-19 pandemic: the Seattle approach.

    abstract：:On January 20, 2020, the first patient with coronavirus disease 2019 (COVID-19) in the United States of America was diagnosed in Washington state, which subsequently experienced rapidly increasing numbers of COVID-19 cases, hospitalizations, and deaths. This placed the Seattle Blood and Marrow Transplant Program at Fr...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/s41409-020-01068-x

    authors： Ueda Oshima M,Sandmaier BM,Petersdorf E,Flowers ME,Hill GR,Lee SJ,Appelbaum FR,Carpenter PA,Baker KS,Connelly-Smith L,McCool A,Elgar S,Pergam SA,Liu C,Stewart FM,Mielcarek M

    更新日期：2020-09-26 00:00:00

  • Curative treatment of autosomal-recessive hyper-IgE syndrome by hematopoietic cell transplantation.

    abstract：:Autosomal-recessive hyper-IgE syndrome (AR-HIES) is a combined immunodeficiency recently found to be associated with mutations of DOCK8. Clinically, this disorder is characterized beside recurrent bacterial complications, in particular by an unusual susceptibility to extensive cutaneous viral complications and by a hi...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.169

    authors： Gatz SA,Benninghoff U,Schütz C,Schulz A,Hönig M,Pannicke U,Holzmann KH,Schwarz K,Friedrich W

    更新日期：2011-04-01 00:00:00

  • Heparin-induced thrombocytopenia after bone marrow transplantation: report of two cases.

    abstract：:Persistent thrombocytopenia and thrombotic complications are commonly observed in bone marrow transplant (BMT) patients. We describe two incidents following BMT in which heparin may have played a contributory role. One patient developed subclavian venous thrombosis following autologous BMT in spite of the severe throm...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Tezcan AZ,Tezcan H,Gastineau DA,Armitage JO,Haire WD

    更新日期：1994-09-01 00:00:00

  • Prospective pilot trial of calcipotriene as a novel topical treatment for acute skin graft versus host disease.

    abstract：:Skin graft versus host disease (GVHD) can affect quality of life in hematopoietic stem cell transplant recipients. Therapeutic options for steroid-refractory GVHD are limited. We report the first prospective pilot study evaluating the topical vitamin D3 analog Calcipotriene (DOVONEX 0.005% cream) for acute skin GVHD i...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-020-01189-3

    authors： Wallace G,Khandelwal P,Myers KC,Perentesis EMR,Lane A,Teusink-Cross A,Smiley K,Davies SM,Jodele S

    更新日期：2021-01-08 00:00:00

  • Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support.

    abstract：:Multiple myeloma (MM) is characterized by the expansion of tumor plasma cells in bone marrow (BM), but neoplastic cells have been consistently detected in peripheral blood (PB). Peripheral blood progenitor cell (PBPC) collections have been widely used to support high-dose therapy for MM patients. A flow cytometric tec...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702085

    authors： Boccadoro M,Omedé P,Dominietto A,Palumbo A,Bringhen S,Giaretta F,Ortolano B,Triolo S,Pileri A

    更新日期：2000-01-01 00:00:00

  • Pegfilgrastim compared with filgrastim for cytokine-alone mobilization of autologous haematopoietic stem and progenitor cells.

    abstract：:Haematopoietic stem and progenitor cells (HSPC) mobilization, using cytokine-alone, is a well-tolerated regimen with predictable mobilization kinetics. Single-dose pegfilgrastim mobilizes HSPC efficiently; however, there is surprisingly little comparative data on its use without chemotherapy for HSPC mobilization. Peg...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2012.145

    authors： Herbert KE,Gambell P,Link EK,Mouminoglu A,Wall DM,Harrison SJ,Ritchie DS,Seymour JF,Prince HM

    更新日期：2013-03-01 00:00:00

  • Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation.

    abstract：:Community-acquired respiratory virus (RV) infections are an important cause of disease in immunocompromised adults with cancer. To investigate the viral etiology, incidence, clinical presentation, and outcome of RV infections in an outpatient cohort of adult bone marrow or peripheral blood stem cell transplant (SCT) r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1704257

    authors： Roghmann M,Ball K,Erdman D,Lovchik J,Anderson LJ,Edelman R

    更新日期：2003-12-01 00:00:00

  • Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.

    abstract：:G-CSF accelerates neutrophil recovery after autologous peripheral blood progenitor cell transplantation (aPBPCT), although the optimal timing for its administration is currently unknown. In order to establish the role and the optimal timing of administration of G-CSF after immunoselected CD34+ aPBPCT, we analyzed the ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1701795

    authors： Piccirillo N,Sica S,Laurenti L,Chiusolo P,La Barbera EO,Sorà F,Leone G

    更新日期：1999-06-01 00:00:00

  • Stem cell enumeration in cord blood vs bone marrow and peripheral blood.

    abstract：:Recent reports have suggested that the total number of autologous or allogeneic hematopoietic stem cell (HSC) infused after high-dose chemotherapy might predict survival, post-transplant morbidity and rate of hematopoietic engraftment. However, HSC capable of long-term multilineage potential are still poorly defined, ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bertolini F,Battaglia M,Lanza A,Gibelli N,Palermo B,Pavesi L,Robustelli della Cuna G

    更新日期：1998-07-01 00:00:00